Condition: Parkinson Disease (PD) · Sponsor: Royan Institute
Dopason is a phase I, open-label, multicenter, single-arm clinical trial designed to evaluate the safety and feasibility of intraputaminal transplantation of human embryonic stem cell-derived dopaminergic progenitor cells (DopaCells) in patients with moderately severe Parkinson's disease.
This description comes directly from the study's public registry record.
Sarvenaz Salahi, MD · 021-23562000 · salahi13639@gmail.com
Always discuss trial participation with your own doctor first.
| Shiraz University of Medical Sciences | Shiraz, Iran | Recruiting |
| Iran University of Medical Sciences | Tehran, Iran | Recruiting |
| Royan Institute | Tehran, Iran | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07572071